WO2013101949A3 - Composition and method for compounded therapy - Google Patents

Composition and method for compounded therapy Download PDF

Info

Publication number
WO2013101949A3
WO2013101949A3 PCT/US2012/071846 US2012071846W WO2013101949A3 WO 2013101949 A3 WO2013101949 A3 WO 2013101949A3 US 2012071846 W US2012071846 W US 2012071846W WO 2013101949 A3 WO2013101949 A3 WO 2013101949A3
Authority
WO
WIPO (PCT)
Prior art keywords
compounded
cream
lamotrigine
topiramate
meloxicam
Prior art date
Application number
PCT/US2012/071846
Other languages
French (fr)
Other versions
WO2013101949A2 (en
Inventor
Jay Richard RAY II
Charles D. HODGE
Original Assignee
JCDS Holdings, LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by JCDS Holdings, LLC filed Critical JCDS Holdings, LLC
Priority to AU2012362418A priority Critical patent/AU2012362418A1/en
Priority to CA2857347A priority patent/CA2857347A1/en
Priority to EP12861175.3A priority patent/EP2797602A2/en
Publication of WO2013101949A2 publication Critical patent/WO2013101949A2/en
Publication of WO2013101949A3 publication Critical patent/WO2013101949A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Anesthesiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present embodiments relate to topically delivered compounded medications. The transdermal cream may include low concentrations of local anesthetics, a NSAID, an anticonvulsant, and/or other active ingredients. The transdermal cream may include lidocaine, prilocaine, meloxicam, and lamotrigine and/or topiramate. Alternatively, the trans dermal cream may include a lidocaine/prilocaine base cream to which is added a fine powder of one or more ground up medications to form a compounded medication. The compounded medication in powder form may be generated from grinding up tablets of NSAIDs, anticonvulsants, nerve depressants, antidepressants, muscle relaxants, NMDA receptor antagonists, opiate or opioid agonists, and/or other agents. The compounded medication in powder form may include meloxicam, lamotrigine, topiramate, other active ingredients, and DMSO or Sterile Water for Irrigation.
PCT/US2012/071846 2011-12-27 2012-12-27 Composition and method for compounded therapy WO2013101949A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU2012362418A AU2012362418A1 (en) 2011-12-27 2012-12-27 Composition and method for compounded therapy
CA2857347A CA2857347A1 (en) 2011-12-27 2012-12-27 Composition and method for compounded therapy
EP12861175.3A EP2797602A2 (en) 2011-12-27 2012-12-27 Composition and method for compounded therapy

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US201113337598A 2011-12-27 2011-12-27
US13/337,598 2011-12-27
US201213409738A 2012-03-01 2012-03-01
US13/409,738 2012-03-01
US13/448,088 2012-04-16
US13/448,088 US9468599B2 (en) 2011-12-27 2012-04-16 Composition and method for compounded therapy
US13/564,525 2012-08-01
US13/564,525 US9724294B2 (en) 2011-12-27 2012-08-01 Composition and method for compounded therapy

Publications (2)

Publication Number Publication Date
WO2013101949A2 WO2013101949A2 (en) 2013-07-04
WO2013101949A3 true WO2013101949A3 (en) 2015-06-11

Family

ID=48655159

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2012/071846 WO2013101949A2 (en) 2011-12-27 2012-12-27 Composition and method for compounded therapy

Country Status (5)

Country Link
US (3) US9468599B2 (en)
EP (1) EP2797602A2 (en)
AU (1) AU2012362418A1 (en)
CA (1) CA2857347A1 (en)
WO (1) WO2013101949A2 (en)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8852638B2 (en) 2005-09-30 2014-10-07 Durect Corporation Sustained release small molecule drug formulation
BRPI0811319A2 (en) 2007-05-25 2015-02-10 Tolmar Therapeutics Inc FLUID COMPOSITION, METHOD FOR FORMATION OF A FLUID COMPOSITION, BIODEGRADABLE IMPLANT FORMED IN SITU, METHOD FOR FORMATION OF A BIODEGRADABLE IMPLANT, KIT, IMPLANT AND TREATMENT METHOD
US9272044B2 (en) 2010-06-08 2016-03-01 Indivior Uk Limited Injectable flowable composition buprenorphine
GB2513060B (en) 2010-06-08 2015-01-07 Rb Pharmaceuticals Ltd Microparticle buprenorphine suspension
US9962391B2 (en) 2011-12-27 2018-05-08 Cmpd Licensing, Llc Composition and method for compounded therapy
US9468599B2 (en) 2011-12-27 2016-10-18 Cmpd Licensing, Llc Composition and method for compounded therapy
US11213500B2 (en) 2011-12-27 2022-01-04 Cmpd Licensing, Llc Composition and method for compounded therapy
US11213501B2 (en) 2011-12-27 2022-01-04 Cmpd Licensing, Llc Composition and method for compounded therapy
US10813897B2 (en) 2011-12-27 2020-10-27 Cmpd Licensing, Llc Composition and method for compounded therapy
GB201311984D0 (en) 2013-07-04 2013-08-21 Univ Cardiff Methods and compounds for preventing or treating osteoarthritis
GB201404139D0 (en) 2014-03-10 2014-04-23 Rb Pharmaceuticals Ltd Sustained release buprenorphine solution formulations
US9801945B2 (en) 2014-04-21 2017-10-31 Heron Therapeutics, Inc. Long-acting polymeric delivery systems
EP3785700A1 (en) 2014-04-21 2021-03-03 Heron Therapeutics, Inc. Compositions of a polyorthoester and an organic acid excipient
PL3134068T3 (en) 2014-04-21 2021-12-20 Heron Therapeutics, Inc. Long-acting polymeric delivery systems
WO2018048460A1 (en) * 2014-04-21 2018-03-15 Heron Therapeutics, Inc. A pharmaceutical composition comprising a delivery system, an amide-type local anesthetic, and meloxicam
US11793783B2 (en) 2015-08-05 2023-10-24 Cmpd Licensing, Llc Compositions and methods for treating an infection
US11684567B2 (en) 2015-08-05 2023-06-27 Cmpd Licensing, Llc Compositions and methods for treating an infection
CN106806338B (en) * 2015-12-01 2021-05-25 四川海思科制药有限公司 Compound lidocaine cream pharmaceutical composition and preparation method thereof
US10231924B2 (en) * 2016-03-23 2019-03-19 Cmpd Licensing, Llc Compounded topical composition and method
AU2017267590A1 (en) * 2016-05-17 2019-01-17 Alberta Veterinary Laboratories Ltd Topical composition for the control of pain in animals
US10525025B2 (en) 2016-11-17 2020-01-07 Cmpd Licensing, Llc Compounded compositions and methods for treating pain
US10966946B2 (en) 2016-11-17 2021-04-06 Cmpd Licensing, Llc Compounded compositions and methods for treating pain
US11737975B2 (en) 2016-11-17 2023-08-29 Cmpd Licensing, Llc Compounded compositions and methods for treating pain
US9999604B2 (en) 2016-11-17 2018-06-19 Cmpd Licensing, Llc Compounded solutions of diclofenac and lidocaine and methods
US11986448B2 (en) 2016-11-17 2024-05-21 Cmpd Licensing, Llc Compounded compositions and methods for treating pain
US10300100B1 (en) 2018-09-27 2019-05-28 King Saud University Extract of Vicia faba beans

Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5993836A (en) * 1998-04-28 1999-11-30 Castillo; James G. Topical anesthetic formulation
US7166641B2 (en) * 2002-10-02 2007-01-23 Yung Shin Pharmaceutical Industrial Co., Ltd. Pharmaceutically acceptable salts containing local anesthetic and anti-inflammatory activities and methods for preparing the same
US20070065463A1 (en) * 2003-06-20 2007-03-22 Ronald Aung-Din Topical therapy for the treatment of migranes, muscle sprains, muscle spasms, spasticity and related conditions
US20070269393A1 (en) * 1999-10-22 2007-11-22 Scott Wepfer Topical anesthetic formulation
US20070269465A9 (en) * 2003-06-19 2007-11-22 Fita Fernando B Anesthetic composition for topical administration comprising lidocaine, prilocaine and tetracaine
US20080233183A1 (en) * 2007-03-22 2008-09-25 Pathfinder Management, Inc. Topical formulations having enhanced bioavailability
US20100016436A1 (en) * 2005-12-07 2010-01-21 Pharmacodex Ltd. Transdermal Administration of Active Agents, in Particular Diclofenac
US20100080797A1 (en) * 2005-08-26 2010-04-01 Yeomans David C Therapy procedure for drug delivery for trigeminal pain
US20100221309A1 (en) * 2001-10-12 2010-09-02 Monosol Rx, Llc Film compositions for delivery of actives
US20100286205A1 (en) * 2007-09-21 2010-11-11 Mccarron Paul Anthony Wound care formulation
US20110015229A1 (en) * 2009-01-06 2011-01-20 Jie Zhang Method of treating neuropathic pain
US20110028460A1 (en) * 2006-03-06 2011-02-03 Fqubed, Inc. Topical formulation
US20110033545A1 (en) * 2009-08-06 2011-02-10 Absize, Inc. Topical pharmaceutical preparations having both a nanoparticle solution and a nanoparticle suspension and methods for the treatment of acute and chronic pain therewith
US20110257257A1 (en) * 2008-10-21 2011-10-20 Novodermix International Limited Composition for treatment of epithelial tissue

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3711602A (en) 1970-10-30 1973-01-16 Crown Zellerbach Corp Compositions for topical application for enhancing tissue penetration of physiologically active agents with dmso
SE7713618L (en) 1977-12-01 1979-06-02 Astra Laekemedel Ab LOCAL ANESTHETIC MIXTURE
US4937078A (en) 1988-08-26 1990-06-26 Mezei Associates Limited Liposomal local anesthetic and analgesic products
JPH07309749A (en) 1994-05-19 1995-11-28 Terumo Corp Flurbiprofen-containing external preparation
US6248789B1 (en) 1996-08-29 2001-06-19 Stuart L. Weg Administration of ketamine to manage pain and to reduce drug dependency
US6290986B1 (en) * 1996-10-24 2001-09-18 Pharmaceutical Applications Associates, Llc Method and composition for transdermal administration of pharmacologic agents
US6572880B2 (en) * 1996-10-24 2003-06-03 Pharmaceutical Applications Associates Llc Methods and transdermal compositions for pain relief
JP3469120B2 (en) 1998-06-12 2003-11-25 矢崎総業株式会社 Communication network and communication device
US6299902B1 (en) * 1999-05-19 2001-10-09 The University Of Georgia Research Foundation, Inc. Enhanced transdermal anesthesia of local anesthetic agents
WO2000074699A1 (en) 1999-06-03 2000-12-14 Johnson & Johnson Consumer France Sas Extracts of feverfew (tanacetum parthenium) against inflammatory disorders
US20030124176A1 (en) 1999-12-16 2003-07-03 Tsung-Min Hsu Transdermal and topical administration of drugs using basic permeation enhancers
AU2003263599A1 (en) * 2002-09-17 2004-04-08 Nippon Boehringer Ingelheim Co., Ltd. Pharmaceutical composition for topical delivery of meloxicam comprising an amine or amine as penetration enhancer.
US7687080B2 (en) 2002-11-25 2010-03-30 Taraxos Inc. Treatment of neuropathy
WO2004091593A2 (en) 2003-04-14 2004-10-28 Pain Therapeutics, Inc. Methods for the treatment of pain comprising opioid antagonists
US20040265364A1 (en) * 2003-06-25 2004-12-30 Binnur Ozturk Neuropathy cream
US7666914B2 (en) 2004-06-03 2010-02-23 Richlin David M Topical preparation and method for transdermal delivery and localization of therapeutic agents
US20060223788A1 (en) 2005-03-29 2006-10-05 Cathcart Clifton H Analgesic composition for topical use
KR20080071185A (en) 2005-11-21 2008-08-01 쉐링-프라우 리미티드 Pharmaceutical compositions comprising buprenorphine
AU2008317307A1 (en) 2007-10-25 2009-04-30 Novartis Ag Powder conditioning of unit dose drug packages
US8535738B2 (en) 2007-12-20 2013-09-17 Elc Management, Llc Methods and compositions for treating skin
US20090162421A1 (en) 2007-12-21 2009-06-25 Paz Arzneimittel-Entwicklungsgesellschaft Mbh Drugs as well as their production and use in the treatment of pain-associated neuropathies
US8889635B2 (en) 2008-09-30 2014-11-18 The Regents Of The University Of Michigan Dendrimer conjugates
US20100226972A1 (en) * 2009-03-06 2010-09-09 Lutz George W Transdermal pain gel
WO2013048453A1 (en) 2011-09-30 2013-04-04 Ray Jay Richard Ii Compounded transdermal pain management
US9724315B2 (en) 2011-09-30 2017-08-08 Cmpd Licensing, Llc Compounded transdermal pain management
US20150359740A1 (en) 2011-12-27 2015-12-17 Cmpd Licensing, Llc Composition and method for compounded therapy
US11213500B2 (en) 2011-12-27 2022-01-04 Cmpd Licensing, Llc Composition and method for compounded therapy
US9468599B2 (en) 2011-12-27 2016-10-18 Cmpd Licensing, Llc Composition and method for compounded therapy
US11213501B2 (en) 2011-12-27 2022-01-04 Cmpd Licensing, Llc Composition and method for compounded therapy

Patent Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5993836A (en) * 1998-04-28 1999-11-30 Castillo; James G. Topical anesthetic formulation
US20070269393A1 (en) * 1999-10-22 2007-11-22 Scott Wepfer Topical anesthetic formulation
US20100221309A1 (en) * 2001-10-12 2010-09-02 Monosol Rx, Llc Film compositions for delivery of actives
US7166641B2 (en) * 2002-10-02 2007-01-23 Yung Shin Pharmaceutical Industrial Co., Ltd. Pharmaceutically acceptable salts containing local anesthetic and anti-inflammatory activities and methods for preparing the same
US20070269465A9 (en) * 2003-06-19 2007-11-22 Fita Fernando B Anesthetic composition for topical administration comprising lidocaine, prilocaine and tetracaine
US20070065463A1 (en) * 2003-06-20 2007-03-22 Ronald Aung-Din Topical therapy for the treatment of migranes, muscle sprains, muscle spasms, spasticity and related conditions
US20110250212A1 (en) * 2005-08-26 2011-10-13 Yeomans David C Therapy procedure for drug delivery for trigeminal pain
US20100080797A1 (en) * 2005-08-26 2010-04-01 Yeomans David C Therapy procedure for drug delivery for trigeminal pain
US20100016436A1 (en) * 2005-12-07 2010-01-21 Pharmacodex Ltd. Transdermal Administration of Active Agents, in Particular Diclofenac
US20110028460A1 (en) * 2006-03-06 2011-02-03 Fqubed, Inc. Topical formulation
US20080233183A1 (en) * 2007-03-22 2008-09-25 Pathfinder Management, Inc. Topical formulations having enhanced bioavailability
US20100286205A1 (en) * 2007-09-21 2010-11-11 Mccarron Paul Anthony Wound care formulation
US20110257257A1 (en) * 2008-10-21 2011-10-20 Novodermix International Limited Composition for treatment of epithelial tissue
US20110015229A1 (en) * 2009-01-06 2011-01-20 Jie Zhang Method of treating neuropathic pain
US20110033545A1 (en) * 2009-08-06 2011-02-10 Absize, Inc. Topical pharmaceutical preparations having both a nanoparticle solution and a nanoparticle suspension and methods for the treatment of acute and chronic pain therewith

Also Published As

Publication number Publication date
US9724294B2 (en) 2017-08-08
AU2012362418A1 (en) 2014-08-21
CA2857347A1 (en) 2013-07-04
US20130165429A1 (en) 2013-06-27
US20150148305A1 (en) 2015-05-28
WO2013101949A2 (en) 2013-07-04
EP2797602A2 (en) 2014-11-05
US20130165430A1 (en) 2013-06-27
US9468599B2 (en) 2016-10-18

Similar Documents

Publication Publication Date Title
WO2013101949A3 (en) Composition and method for compounded therapy
SG195375A1 (en) Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
GB2502485A (en) Medicament delivery device for administration of opioid antagonists including formulations for naloxone
MX354125B (en) A combination of an opioid agonist and an opioid antagonist in the treatment of parkinson's disease.
AR084932A1 (en) OPHTHALMIC COMPOSITION INCLUDING AN ANDROGEN AND ITS USE FOR THE MANUFACTURE OF A USEFUL MEDICINAL PRODUCT FOR THE TREATMENT OF AN EYE DISEASE RESULTING FROM AN ANDROGENIC DEFICIENCY
WO2009029958A3 (en) Implantable delivery device
TN2015000244A1 (en) Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
MX2014008284A (en) Delayed-release formulation for reducing the frequency of urination and method of use thereof.
MY173582A (en) Extended-release formulation for reducing the frequency of urination and method of use thereof
NZ595467A (en) Sublingual pharmaceutical composition comprising a neutral oil
MX348933B (en) Compositions, dosage forms, and coadministration of an opioid agonist compound and an analgesic compound.
AU2010212580A8 (en) Stable pharmaceutical composition for atherosclerosis
MY174090A (en) Extended-release formulation for reducing the frequency of urination and method of use thereof
PH12014502331A1 (en) Orally available pharmaceutical formulation suitable for improved management of movement disorders
MY196998A (en) Deuterated 1-piperazino-3-phenyl indanes for treatment of schizophrenia
PH12014502407A1 (en) New alfentanil composition for the treatment of acute pain
AR086491A1 (en) PHARMACEUTICAL COMPOSITION INCLUDING FEXOFENADINE
MXPA06000760A (en) Stable pharmaceutical composition containing carisoprodol and meloxicam.
WO2016193454A3 (en) Dosage of naloxone
MY166773A (en) Deuterated 1-piperazino-3-phenyl indanes for treatment of schizophrenia
TN2013000503A1 (en) Deuterated 1-piperazino-3-phenyl indanes for treatment of schizophrenia
UA61103U (en) pharmaceutical composition for the treatment of multidrug-resistant tuberculosis
TN2013000429A1 (en) Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
RU2013105212A (en) APPLICATION OF PRO-Gly-Pro-Val TETREPEPTIDE AS A MEANS FOR PREVENTION AND TREATMENT OF LIPID METABOLISM DISORDERS, METHOD OF PREVENTION AND TREATMENT OF LIPID METABOLISM VIOLATIONS, PHARMACEUTICAL COMPOSITION
IN2013MU03390A (en)

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12861175

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2857347

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

REEP Request for entry into the european phase

Ref document number: 2012861175

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2012861175

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2012362418

Country of ref document: AU

Date of ref document: 20121227

Kind code of ref document: A